BIOMAT Database Logo BIOMAT Database Logo

Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via O-->N acyloxy migration of P1 moiety. 2003

Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA. wieslaw.m.kazmierski@gsk.com

We have developed a new approach to prodrugs, which utilizes a pH-induced intramolecular O-->N migration of an acyloxy group in carbonate moiety to a free amino moiety at neutral pH. This method is exemplified by facile rearrangement of highly water-soluble prodrug 3 to carbamate 4, a close analogue of HIV-1 protease inhibitor Amprenavir. The O-->N acyloxy migration is unprecedented in the context of prodrugs and it enables a high atom economy due to recycling of the 'pro' moiety.

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002219 Carbamates Derivatives of carbamic acid, H2NC( Carbamate,Aminoformic Acids,Carbamic Acids,Acids, Aminoformic,Acids, Carbamic
D002627 Chemistry, Physical The study of CHEMICAL PHENOMENA and processes in terms of the underlying PHYSICAL PHENOMENA and processes. Physical Chemistry,Chemistries, Physical,Physical Chemistries
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
March 2012, Bioorganic & medicinal chemistry letters,
Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration.
December 2002, Bioorganic & medicinal chemistry,
Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
March 2008, Bioorganic & medicinal chemistry,
Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
Cage dimeric N-acyl- and N-acyloxy-4-aryl-1,4-dihydropyridines as first representatives of a novel class of HIV-1 protease inhibitors.
November 1999, Archiv der Pharmazie,
Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
New, potent P1/P2-morpholinone-based HIV-protease inhibitors.
October 2006, Bioorganic & medicinal chemistry letters,
Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease.
December 2002, Bioorganic & medicinal chemistry letters,
Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.
February 2005, Bioorganic & medicinal chemistry,
Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
Synthesis of novel cyclic urea based HIV-1 protease inhibitors.
November 1995, Drug design and discovery,
Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
August 2006, Journal of medicinal chemistry,
Wieslaw M Kazmierski, and Patricia Bevans, and Eric Furfine, and Andrew Spaltenstein, and Hanbiao Yang
Water-soluble prodrugs of dipeptide HIV protease inhibitors based on O-->N intramolecular acyl migration: Design, synthesis and kinetic study.
January 2004, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!